AstraZeneca's Imfinzi combined with BCG therapy showed improved disease-free survival in high-risk non-muscle-invasive bladder cancer patients in the POTOMAC Phase III trial. The study assessed 1,018 subjects and demonstrated a positive outcome without safety concerns.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing